SEC ownership of Monopar Therapeutics

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001645469.

Comparable stake leader

Janus Henderson Group Ltd.

Disclosed value leader

Jupiter Topco LLC

Comparable rows

50/50

Latest evidence

26 Aug 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
50 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
Janus Henderson Group Ltd.
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
26 Aug 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001645469
Issuer location
Wilmette, IL

Ownership snapshot

Top shareholders of Monopar Therapeutics (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Janus Henderson Group Ltd.
Disclosed value leader
Jupiter Topco LLC
Comparable rows
50/50
Latest evidence
26 Aug 2026
13D/G 13F 3/4/5 Lead comparable stake: 20% 13D/G row: Janus Henderson Group Ltd. Showing 1-8 of 50 holder rows.

Quick read

Janus Henderson Group Ltd. leads the comparable SEC ownership view at 20%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Janus Henderson Group Ltd.'s linked filing trail.
Comparable ownership Top 5
Janus Henderson Group Ltd. 20%
RA CAPITAL MANAGEMENT, L.P. 9.9%
ASTRAZENECA PLC 7.8%
Adage Capital Management, L.P. 4.8%
Saturn V Capital Management LP 4.7%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Janus Henderson Group Ltd.
13D/G
JANUS HENDERSON GROUP PLC
20%
$105,138,701
1,287,368 shares
+$9,391,992 30 Sep 2025
RA CAPITAL MANAGEMENT, L.P.
13F 13D/G
Company
9.9%
from 13D/G
$61,776,696
667,207 shares
— 30 Jun 2026
ASTRAZENECA PLC
13D/G
7.8%
$34,126,392
522,667 shares
$0 31 Dec 2025
Adage Capital Management, L.P.
13D/G
4.8%
$31,485,818
324,195 shares
-$9,712,000 30 Jun 2026
Saturn V Capital Management LP
13D/G 13F
Company
4.7%
$30,435,854
313,384 shares
-$3,131,343 30 Jun 2026
Hendricks Diane
3/4/5
10%+ Owner
8.5%
$50,213,802
567,580 shares
— 16 Dec 2025
Tactic Pharma LLC
3/4/5
10%+ Owner
4.1%
$17,303,519
272,026 shares
— 24 Sep 2025
Patrice Rioux
3/4/5
Acting Chief Medical Officer
0.08%
$563,531
5,065 shares
-$111 26 Aug 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to selling over the last 12 months. Net value: -$3,603,328.

Buys
$104,925
Insiders: 1
Sells
$3,708,253
Insiders: 5
Net
-$3,603,328
Shares: -39,910
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 1,500 Shares: 41,410
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 36,289 $0 $3,364,364 -$3,364,364
3-6 0 0 $0 $0 $0
6-9 0 0 $0 $0 $0
9-12 1,500 5,121 $104,925 $343,889 -$238,964

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-18 of 18 reporting-owner rows connected to Monopar Therapeutics. Open a relationship link for the CIK-to-CIK filing trail.

Rows
18
Largest Forms 3/4/5 holder
Hendricks Diane
Net 12M change
-$3,603,328
Latest report
30 Sep 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Hendricks Diane 10%+ Owner $50,213,802 Mixed 16 Dec 2025
Chandler Robinson Chief Executive Officer, Director $18,959,333 -$2,556,851 -12% Mixed 30 Sep 2026
Tactic Pharma LLC 10%+ Owner $17,303,519 Filing P/S 24 Sep 2025
Andrew Cittadine Chief Operating Officer $6,511,629 Mixed 30 Sep 2026
Kim R. Tsuchimoto Director $1,063,488 -$455,567 -30% Median 26 Aug 2026
Raymond Anderson Director $607,417 -$351,835 -37% Filing P/S 25 Aug 2026
Arthur J. Klausner Director $596,604 -$343,889 -37% Filing P/S 18 Dec 2025
Patrice Rioux Acting Chief Medical Officer $563,531 -$111 -0.02% Filing P/S 26 Aug 2026
Christopher M. Starr Director $538,894 Mixed 02 Dec 2025
Lavina Talukdar Director $308,022 Mixed 02 Dec 2025
Quan Anh Vu Chief Financial Officer $245,826 +$104,925 +74% Median 30 Sep 2026
Michael J. Brown Director $136,941 Mixed 31 Dec 2023
Andrew Paul Mazar Chief Scientific Officer, Director $94,434 Mixed 31 Mar 2022
Karthik Radhakrishnan Chief Financial Officer $10,447 Mixed 28 Oct 2024
TacticGem LLC 10%+ Owner $0 Mixed 09 Dec 2024
Nicole Sweeny Director Mixed 26 Jun 2026
Susan Rodriguez Ccso Mixed 02 Mar 2026
Jose Octavio Pinto Costa Filho Chief Medical Officer Mixed 12 Jul 2021

Recent insider transactions for Monopar Therapeutics

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Andrew Cittadine MNPR Common Stock Tax liability -3.24% -1,944 58,054 30 Sep 2026 Direct
Andrew Cittadine MNPR Common Stock Options Exercise 7.88% 4,384 59,998 30 Sep 2026 Direct
Andrew Cittadine MNPR Restricted Stock Unit Options Exercise -11.1% -4,384 35,115 30 Sep 2026 Direct
Chandler Robinson MNPR Common Stock Tax liability -3.98% -4,344 104,724 30 Sep 2026 Direct
Chandler Robinson MNPR Common Stock Options Exercise 9.87% 9,801 109,068 30 Sep 2026 Direct
Chandler Robinson MNPR Restricted Stock Unit Options Exercise -10.5% -9,801 83,602 30 Sep 2026 Direct
Quan Anh Vu MNPR Common Stock Tax liability -6.35% -180 2,655 30 Sep 2026 Direct
Quan Anh Vu MNPR Common Stock Options Exercise 27.6% 614 2,835 30 Sep 2026 Direct
Quan Anh Vu MNPR Restricted Stock Unit Options Exercise -7.14% -614 7,984 30 Sep 2026 Direct
Chandler Robinson MNPR Common Stock Sale -22.6% $2,556,851 $88.00 -29,056 99,267 24 Sep 2026 Direct
Chandler Robinson MNPR Common Stock Options Exercise 29.3% 29,056 128,323 24 Sep 2026 Direct
Chandler Robinson MNPR Stock Option Options Exercise -65.9% -29,056 15,044 24 Sep 2026 Direct
Kim R. Tsuchimoto MNPR Common Stock Sale -100% $455,567 $111.39 -4,090 0 26 Aug 2026 Direct
Kim R. Tsuchimoto MNPR Common Stock Options Exercise 4,090 4,090 26 Aug 2026 Direct
Kim R. Tsuchimoto MNPR Stock Option Options Exercise 101% 4,090 8,140 26 Aug 2026 Direct
Patrice Rioux MNPR Common Stock Sale -0.02% $111 $111.26 -1 5,065 26 Aug 2026 Direct
Patrice Rioux MNPR Common Stock Options Exercise 37.4% 1,380 5,066 26 Aug 2026 Direct
Patrice Rioux MNPR Stock Option Options Exercise 1,380 0 26 Aug 2026 Direct
Raymond Anderson MNPR Common Stock Sale -36.9% $351,835 $111.98 -3,142 5,373 25 Aug 2026 Direct
Raymond Anderson MNPR Common Stock Options Exercise 58.5% 3,142 8,515 25 Aug 2026 Direct
Raymond Anderson MNPR Stock Option Options Exercise 929.6% 3,142 3,480 25 Aug 2026 Direct
Quan Anh Vu MNPR Common Stock Tax liability -18.6% -507 2,221 30 Jun 2026 Direct
Quan Anh Vu MNPR Common Stock Options Exercise 81.9% 1,228 2,728 30 Jun 2026 Direct
Quan Anh Vu MNPR Restricted Stock Unit Options Exercise -12.5% -1,228 8,598 30 Jun 2026 Direct
Chandler Robinson MNPR Common Stock Tax liability -3.95% -4,084 99,267 30 Jun 2026 Direct
Chandler Robinson MNPR Common Stock Options Exercise 14.2% 12,873 103,351 30 Jun 2026 Direct
Chandler Robinson MNPR Restricted Stock Unit Options Exercise -12.1% -12,873 93,403 30 Jun 2026 Direct
Andrew Cittadine MNPR Common Stock Tax liability -3.99% -2,309 55,614 30 Jun 2026 Direct
Andrew Cittadine MNPR Common Stock Options Exercise 9.98% 5,254 57,923 30 Jun 2026 Direct
Andrew Cittadine MNPR Restricted Stock Unit Options Exercise -11.7% -5,254 39,499 30 Jun 2026 Direct
Nicole Sweeny MNPR Stock Options Award 1,284 1,284 26 Jun 2026 Direct
Chandler Robinson MNPR Common Stock Tax liability -2.13% -1,972 90,478 31 Mar 2026 Direct
Chandler Robinson MNPR Common Stock Options Exercise 7.85% 6,732 92,450 31 Mar 2026 Direct
Chandler Robinson MNPR Restricted Stock Unit Options Exercise -5.96% -6,732 106,276 31 Mar 2026 Direct
Andrew Cittadine MNPR Common Stock Tax liability -2.9% -1,571 52,669 31 Mar 2026 Direct
Andrew Cittadine MNPR Common Stock Options Exercise 6.93% 3,514 54,240 31 Mar 2026 Direct
Andrew Cittadine MNPR Restricted Stock Unit Options Exercise -7.28% -3,514 44,753 31 Mar 2026 Direct
Susan Rodriguez MNPR Stock Options Award 48,728 48,728 02 Mar 2026 Direct
Patrice Rioux MNPR Stock Option Award 2,000 2,000 01 Jan 2026 Direct
Chandler Robinson MNPR Common Stock Tax liability -2.9% -2,558 85,718 31 Dec 2025 Direct
Chandler Robinson MNPR Common Stock Options Exercise 11% 8,724 88,276 31 Dec 2025 Direct
Chandler Robinson MNPR Restricted Stock Unit Options Exercise -7.17% -8,724 113,008 31 Dec 2025 Direct
Andrew Cittadine MNPR Common Stock Tax liability -3.59% -1,889 50,726 31 Dec 2025 Direct
Andrew Cittadine MNPR Common Stock Options Exercise 8.96% 4,326 52,615 31 Dec 2025 Direct
Andrew Cittadine MNPR Restricted Stock Unit Options Exercise -8.23% -4,326 48,267 31 Dec 2025 Direct
Quan Anh Vu MNPR Common Stock Purchase $104,925 $69.95 1,500 1,500 26 Dec 2025 Direct
Arthur J. Klausner MNPR Common Stock Sale -36.9% $343,889 $67.15 -5,121 8,762 18 Dec 2025 Direct
Diane Hendricks MNPR Common Stock Other -7.12% -43,499 567,580 16 Dec 2025 See footnote
Arthur J. Klausner MNPR Common Stock Other 124.9% 7,710 13,883 16 Dec 2025 Direct
Andrew Cittadine MNPR Restricted Stock Units Award 36% 13,919 52,593 02 Dec 2025 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .